Screening for Early Diagnosis of Nose Cancer

NARecruitingINTERVENTIONAL
Enrollment

20,000

Participants

Timeline

Start Date

November 8, 2022

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2027

Conditions
Nasopharyngeal Carcinoma
Interventions
DIAGNOSTIC_TEST

EBV biomarker testing

"15 ml of blood will be collected for EBV EA IgA serology and plasma EBV DNA testing by a trained nursing/phlebotomy staff. If the initial plasma EBV DNA test is positive, a second blood draw will be performed for repeat plasma EBV DNA testing.~Additionally, 2-3 ml of saliva will be collected for EBV strain identification, however, this information is not used for risk stratification in this study.~Demographic characteristics, clinical history and symptoms will be collected through a questionnaire."

Trial Locations (2)

Unknown

RECRUITING

National University Hospital, Singapore

RECRUITING

National University Polyclinics, Singapore

Sponsors
All Listed Sponsors
collaborator

National Medical Research Council (NMRC), Singapore

OTHER_GOV

collaborator

Genome Institute of Singapore

OTHER

collaborator

Pathnova Laboratories, Singapore

UNKNOWN

collaborator

National University of Singapore

OTHER

lead

National University Hospital, Singapore

OTHER